Literature DB >> 32815084

Novel rhein-phospholipid complex targeting skin diseases: development, in vitro, ex vivo, and in vivo studies.

Heba M K Ebada1, Maha M A Nasra2, Yosra S R Elnaggar2,3, Ossama Y Abdallah2.   

Abstract

Rhein (RH), an anthraquinone derivative, has proven to be a promising molecule for treating several skin disorders thanks to its pleiotropic pharmacological activities like antimicrobial, antifungal, antioxidant, and anticancer. However, RH's low water and oil solubility and poor skin permeability halted its topical delivery. This is the first work to investigate the expediency of tailoring a rhein-phospholipid complex (RH-PLC) to improve RH challenging physicochemical and skin permeability properties. The phospholipid complex was prepared by employing different methods and different RH/PL molar ratios. RH-PLC was successfully developed at a stoichiometric ratio of 1:1 using a novel pH-dependent method where at a certain pH, it exhibits the highest complexation efficiency (95%). RH-PLC formation was confirmed using FTIR, DSC, and XRPD analysis. RH-PLC showed a significant increase in water and n-octanol solubility. RH-PLC was self-assembled upon dispersion into water forming nano-sized particles (196.6 ± 1.6 nm) with high negatively charged surface (- 29.7 ± 2.45 mV). RH-PLC exhibited a significant 3.3- and 2.46-fold increase in ex vivo and in vivo skin permeability when compared with RH suspension, respectively. Confocal microscopy study confirmed the ability of RH-PLC to penetrate deeply into rat skin. Besides, skin irritation test on healthy rats indicated compatibility and safety of RH-PLC. Conclusively, phospholipid complex might be a suitable approach to improve permeability of RH and other promising abandoned poor-permeable drugs. The proposed RH-PLC is expected to be a major progressive step toward the development of a topical RH formulation. Graphical abstract.

Entities:  

Keywords:  Phospholipid complex; Rhein; Skin penetration; Topical application

Mesh:

Substances:

Year:  2021        PMID: 32815084     DOI: 10.1007/s13346-020-00833-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  45 in total

1.  Antifungal activity of anthraquinone derivatives from Rheum emodi.

Authors:  S K Agarwal; S S Singh; S Verma; S Kumar
Journal:  J Ethnopharmacol       Date:  2000-09       Impact factor: 4.360

2.  Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun.

Authors:  Jin Hyoung Cho; Jung-Il Chae; Jung-Hyun Shim
Journal:  Oncol Rep       Date:  2017-02-07       Impact factor: 3.906

3.  Anticandidal activity of Cassia fistula and its effect on ergosterol biosynthesis.

Authors:  Sheikh Shreaz; Nikhat Manzoor; Luqman A Khan; M Moshahid A Rizvi
Journal:  Pharm Biol       Date:  2011-05-18       Impact factor: 3.503

4.  Global transcriptional response of Staphylococcus aureus to rhein, a natural plant product.

Authors:  Lu Yu; Hua Xiang; Junwen Fan; Dacheng Wang; Feng Yang; Na Guo; Qi Jin; Xuming Deng
Journal:  J Biotechnol       Date:  2008-04-29       Impact factor: 3.307

5.  [Percutaneous permeability of rhein at shenque acupoint in vitro].

Authors:  Ling Feng; Mei-Hong Ding; Qin Shen; Qiu-Hua Sun; Sen-Lin Shi
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2016-04

Review 6.  Anthraquinones As Pharmacological Tools and Drugs.

Authors:  Enas M Malik; Christa E Müller
Journal:  Med Res Rev       Date:  2016-04-25       Impact factor: 12.944

7.  Rhein inhibits TPA-induced activator protein-1 activation and cell transformation by blocking the JNK-dependent pathway.

Authors:  Shigang Lin; Jian-Jian Li; Makoto Fujii; De-Xing Hou
Journal:  Int J Oncol       Date:  2003-04       Impact factor: 5.650

Review 8.  A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient.

Authors:  Hao Sun; Guangwen Luo; Dahui Chen; Zheng Xiang
Journal:  Front Pharmacol       Date:  2016-08-17       Impact factor: 5.810

9.  Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.

Authors:  Verena Wally; Alain Hovnanian; Juliette Ly; Hana Buckova; Victoria Brunner; Thomas Lettner; Michael Ablinger; Thomas K Felder; Peter Hofbauer; Martin Wolkersdorfer; Florian B Lagler; Wolfgang Hitzl; Martin Laimer; Sophie Kitzmüller; Anja Diem; Johann W Bauer
Journal:  J Am Acad Dermatol       Date:  2018-02-02       Impact factor: 11.527

10.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123

View more
  2 in total

1.  Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma.

Authors:  Aya M Khallaf; Riham M El-Moslemany; Mahmoud F Ahmed; Mahmoud H Morsi; Nawal M Khalafallah
Journal:  Int J Nanomedicine       Date:  2022-01-11

2.  Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment.

Authors:  Heba M K Ebada; Maha M A Nasra; Rasha A Nassra; Ossama Y Abdallah
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.